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Abstract
Background: In a previous report by our group, high levels of apolipoprotein E (apoE) were demonstrated to be associated
with risk of incident cardiovascular disease in women with high levels of C-reactive protein (CRP) in the setting of both
low (designated as HR1 subjects) and high (designated as HR2 subjects) levels of high-density lipoprotein cholesterol (HDL-
C). To assess whether apolipoprotein A-II (apoA-II) plays a role in apoE-associated risk in the two female groups.
Methodology/Principal: Outcome event mapping, a graphical data exploratory tool; Cox proportional hazards multivariable
regression; and curve-fitting modeling were used to examine apoA-II influence on apoE-associated risk focusing on HDL
particles with apolipoprotein A-I (apoA-I) without apoA-II (LpA-I) and HDL particles with both apoA-I and apoA-II (LpA-I:A-II).
Results of outcome mappings as a function of apoE levels and the ratio of apoA-II to apoA-I revealed within each of the two
populations, a high-risk subgroup characterized in each situation by high levels of apoE and additionally: in HR1, by a low
value of the apoA-II/apoA-I ratio; and in HR2, by a moderate value of the apoA-II/apoA-I ratio. Furthermore, derived
estimates of LpA-I and LpA-I:A-II levels revealed for high-risk versus remaining subjects: in HR1, higher levels of LpA-I and
lower levels of LpA-I:A-II; and in HR2 the reverse, lower levels of LpA-I and higher levels of LpA-I:A-II. Results of multivariable
risk modeling as a function of LpA-I and LpA-I:A-II (dichotomized as highest quartile versus combined three lower quartiles)
revealed association of risk only for high levels of LpA-I:A-II in the HR2 subgroup (hazard ratio 5.31, 95% CI 1.12–25.17,
p=0.036). Furthermore, high LpA-I:A-II levels interacted with high apoE levels in establishing subgroup risk.
Conclusions/Significance: We conclude that apoA-II plays a significant role in apoE-associated risk of incident CVD in
women with high levels of HDL-C and CRP.
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Introduction
There is growing interest in the notion that functional
properties of high-density lipoprotein (HDL) [1–3] are impor-
tant factors contributing to protection against cardiovascular
disease (CVD) risk in addition to HDL quantity. However,
evidence is also accumulating to suggest that HDL athero-
protective functionality may be degraded in the setting of
inflammation and oxidative stress; and moreover, that such
conditions may actually result in dysfunctional transformation of
HDL from anti-atherogenic to pro-atherogenic [4–8]. To
investigate this notion in human populations, we have been
studying incident and recurrent CVD risk in individuals with
concurrently high levels of C-reactive protein (CRP), reflective
of inflammatory status, and HDL cholesterol (HDL-C). Subjects
with high HDL-C levels were chosen for study instead of
subjects with low HDL-C levels to avoid potential confounding
of results given the well-known association of low HDL-C with
risk on its own. Also in regard to the choice of high HDL-C
levels, it should be noted that CVD risk associations have been
reported in multiple previous studies [9–20]. Using this
approach we have identified increased risk of incident [21–23]
as well as recurrent [24,25] CVD risk in populations with
concurrently high levels of HDL-C and CRP.
As anti-atherogenic properties of HDL are thought to derive
from multiple HDL particle constituents including [7] apolipo-
proteins (apoA-I, apoA-II, and apoE), enzymes (paraoxonase-1,
lecithin-cholesterol acyltransferase (LCAT), and glutathione per-
oxidase), and lipid transfer proteins (cholesteryl ester transfer
protein (CETP) and phospholipid transfer protein (PLTP)), we
recently studied and reported findings focusing on apoE in this
context. Results demonstrated risk of incident CVD in association
with high apoE levels in women with concurrently high levels of
HDL-C and CRP [23]. In the current work, we sought to extend
these studies in the same population by investigating a potential
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39110relationship in the context of risk between apoE and apoA-II,
another major constituent of HDL.
ApoA-II [26–30] occurs in plasma as a dimer of two 77-amino
acid chains linked by a disulfide bridge; and after apoA-I, it is the
second major protein component of HDL accounting for
approximately 20% of HDL total protein. In terms of lipoprotein
physiology, the role of apoA-II has not been fully characterized;
however, it is thought to play an important role in triglyceride
metabolism both from animal and human studies [26,27,30]. In
this regard, recent findings attribute to apoA-II, inhibitory effects
on lipoprotein lipase-mediated hydrolysis of triglyceride-rich
particles [31,32]; however, additional associations of apoA-II have
been reported for a variety of protein factors including hepatic
lipase (HL), lipoprotein lipase (LPL), endothelial lipase, CETP,
PLTP, and LCAT [26,27,33]. For apoA-II and atherosclerotic
risk, the situation is again not fully characterized as apoA-II has
been associated with both increased and decreased risk [33–35].
To extend our previous findings of high apoE-associated risk in
women with concurrently high levels of HDL-C and CRP [23] in
terms of a potential relationship with apoA-I and apoA-II, we
developed a modeling approach utilizing observed levels of HDL-
C, apoA-I, and apoA-II for the estimation of concentrations of the
two major HDL particle subclasses [26,27], LpA-I (containing
apoA-I but not apoA-II) and LpA-I:A-II (containing apoA-I and
apoA-II). With resultant estimated values for LpA-I and LpA-I:A-
II particle concentrations, multivariable risk models were con-
structed. Results demonstrated risk association for high levels of
LpA-I:A-II. Additionally, there was interaction of LpA-I:A-II with
apoE in establishment of risk.
Materials and Methods
Ethics Statement
The PREVEND (Prevention[of Renal and Vascular Endstage
Disease) study was approved by the Medical Ethics Committee of
the University of Groningen, the Netherlands; written informed
consent was obtained from all subjects. Detailed descriptions of
definitions and data acquisition techniques were reported previ-
ously [21–23,36–38].
Study Populations
The study population was drawn from PREVEND (http://
www.prevend.org/) [36], a prospective longitudinal study of
albuminuria in predicting cardiovascular disease [37] and renal
disease [38]. All inhabitants of the city of Groningen, the
Netherlands (28–75 years of age, N=85,421) were sampled by
Figure 1. Flow diagram of study design.
doi:10.1371/journal.pone.0039110.g001
Figure 2. Outcome event map as a function of apoA-II/apoA-I
ratio and apoE ranks in the total study population of women
and men with iso-contour line of risk at 5.3% superimposed.
doi:10.1371/journal.pone.0039110.g002
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for the period, 1997–1998 and they were requested to supply an
early morning urine specimen. Response rate was 47.8%. Study
subjects included all those with urinary albumin concentrations
$10 mg/L and a group of randomly selected subjects with urinary
albumin ,10 mg/L. Insulin-using diabetics and pregnant women
were excluded. This gave 8592 study subjects that were equally
divided by gender (median age - 48 years). Cardiovascular
outcome events included cardiovascular mortality and any of the
following at hospitalization: non-fatal MI (36.9%), ischemic heart
disease (26.4%), percutaneous transluminal coronary angioplasty
(19.2%), coronary artery bypass grafting (12.5%), and fatal MI
(5.0%). Mortality data were from the municipal register. Cause of
death was obtained by linking death certificate number to primary
cause of death (Dutch Central Bureau of Statistics). Cardiovascular
hospitalization morbidity data were from PRISMANT (Dutch
national registry of hospital discharge diagnoses). Follow-up time
was date of initially requested urine collection in 1997 to date of
either first CVD event or study termination (31 December 2005) if
no CVD event.
The six study groups of the current work consisted of sub-
cohorts of female and male subjects previously identified [21–23]
using outcome event mapping, a graphical exploratory data
analysis tool [25,39]. Subgroups were characterized as follows:
female (N=879) and male (N=764) high-risk subgroups having
concurrently low levels of HDL-C and high levels of CRP
(henceforth designated HR1), female (N=508) and male (N=374)
high-risk subgroups having concurrently high levels of HDL-C and
high levels of CRP (henceforth designated HR2), and female
(N=2232) and male (N=1813) lower-risk background subgroups
of remaining subjects (henceforth designated BG). All-cause
mortality rates (%) and respective % of these due to CVD for
the subgroups were as follows: females, BG - 2.0%/11.1%, HR1 -
3.8%/15.2%, and HR2 - 2.8%/14.3%; and males, BG - 2.9%/
13.2%, HR1 - 3.8%/27.6%, and HR2 - 10.4%/28.2%. Fractions
of mortalities due to CVD did not differ among the female
subgroups (p=0.86) nor among the male subgroups (p=0.15).
Previous results of univariate modeling in the context of risk
associations with apoE levels demonstrated apoE as a predictor of
risk in both the low HDL-C/high CRP subgroup and high HDL-
C/high CRP subgroups but only in women [23]. Initial study
exclusions for PREVEND included insulin-using diabetics and
pregnancy. For the current study, further exclusions were for
diabetes mellitus, renal disease, previous CVD, incomplete
laboratory results, and CRP levels $10 mg/L (to avoid con-
founding by inter-current illness). Median follow-up time was
7.6 years. Metabolic syndrome was assessed according to ATP III
criteria.
Blood Biomarkers
Biomarker analyses were performed on serum and plasma
samples prepared from venous blood from subjects fasted
overnight and after fifteen minutes of rest. Levels of total
cholesterol, HDL-C, triglycerides, apoA1, apoB, glucose, and
high sensitivity CRP were determined as described previously
[21,40]. Immunonephelometry (BNII, Dade Behring, Marburg,
Figure 3. Outcome event maps as a function of apoA-II/apoA-I
ratio and apoE ranks in women for: A. the background
subgroup (BG); B. the low HDL-C/high CRP subgroup (HR1)
with iso-contour line of risk at 5.3% superimposed; and C. the
high HDL-C/high CRP subgroup (HR2) with iso-contour line of
risk at 5.3% superimposed.
doi:10.1371/journal.pone.0039110.g003
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levels were estimated using the Friedewald equation.
Estimation of LpA-I and LpA-I:A-II Concentrations from
Observed HDL-C, apoA-I, and apoA-II Concentrations
LpA-I and LpA-I:A-II particle concentrations were estimated in
four steps: 1. expressing LpA-I and LpA-I:A-II concentrations as
functions of apoA-I, apoA-II, and the average number of apoA-I
and apoA-II molecules per particle; 2. expressing HDL-C as a
function of apoA-I, apoA-II, and the average number of apoA-I
and apoA-II molecules per particle such that multiple linear
regression analysis results in coefficients of the apoA-I and apoA-II
terms that provide a basis for estimation of the average number of
apoA-I and apoA-II molecules per particle; 3. numerical analysis
for the determination of the average number of apoA-I and apoA-
II molecules per LpA-I and LpA-I:A-II particles; and 4. estimation
of LpA-I and LpA-I:A-II levels from observed values of apoA-I
and apoA-II concentrations and the estimated values of the
average number of apoA-I and apoA-II molecules per LpA-I and
LpA-I:A-II particles as per step 1.
1. Expressions for LpA-I and LpA-I:A-II particle
concentrations. Concentrations of HDL particles containing
apoA-I without apoA-II(LpA-I) and HDL particles containing
apoA-I with apoA-II (LpA-I:A-II) were estimated by first assuming
that the sum of apoA-I concentrations associated with each type of
the two HDL particles should equal the measured apoA-I
concentration as follows:
apoA-I~N   LpA-Izn   LpA-I : A-II ð1Þ
where N is the average number of apoA-I molecules per LpA-I
particle and n is the average number of apoA-I molecules per
LpA-I:A-II particle; and second, that the apoA-II concentration
should reflect the LpA-I:A-II concentration as follows:
apoA-II~m   LpA-I : A-II ð2Þ
where m is the average number of apoA-II molecules per LpA-I:A-
II particle. An expression for LpA-I:A-II particle concentration
was directly derived from equation (2) to give:
LpA-I : A-II~(1=m)   apoA-II ð3Þ
while an expression for LpA-I was obtained by substituting the
value of LpA-I:A-II from equation (3) into equation (1) to give:
LpA-I~(1=N)   apoA-I{(n=(N   m))   apoA-II ð4Þ
This results in expressions for LpA-I and LpA-I:A-II involving
measured apoA-I and apoA-II levels and three unknown
parameters (N, n, and m).
2. Estimation of HDL-C levels as a function of apoA-I and
apoA-II levels. To estimate HDL particle concentration
(HDL), a mass balance equation was formulated in terms of
LpA-I and LpA-I:A-II particle concentrations as follows:
Figure 4. Outcome event maps as a function of apoA-II/apoA-I
ratio and apoE ranks in men for: A. the background subgroup
(BG); B. the low HDL-C/high CRP subgroup (HR1); and C. the
high HDL-C/high CRP subgroup (HR2).
doi:10.1371/journal.pone.0039110.g004
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where each term represents the respective particle concentrations
and the assumption is that HDL exists totally either as LpA-I or
LpA-I:A-II. Substitution of the values of LpA-I from equation (4)
and LpA-I:A-II from equation (3) into equation (5) gives:
HDL~(1=N)   apoA-Iz(1=m)   (1{(n=N))   apoA-II ð6Þ
However, HDL particle concentration was not measured in the
study, but rather HDL-C. To re-express equation (6) in terms of
HDL-C, note that:
HDL~k   HDL-C ð7Þ
where k is a linear proportionality constant relating the two.
Substituting the value of HDL from equation (7) into equation (6)
and solving for HDL-C gives:
HDL-C~(1=(N   k))   apoA-Iz(1=(m   k)) 
(1{(n=N))   apoA-II
ð8Þ
The expressions for the coefficients of apoA-I and apoA-II of
equation (8) involve only constants thus enabling equation (8) to be
re-expressed as:
HDL-C~k1   apoA-Izk2   apoA-II ð9Þ
where k1 and k2 are constants defined as follow:
k1{(1=k   N) ð10Þ
k2~(1=(k   m))   (1{(n=N)) ð11Þ
3. Estimation of average number of apoA-I and apoA-II
molecules per LpA-I and LpAI:A-II particle. Dividing k2
from equation (11) by k1 from equation (10) results in an
expression for the ratio of k2/k1. This ratio is a function of N, n,
and m but not k as follows:
k2=k1~(N=m)   (1{(n=N)) ð12Þ
Observed HDL-C, apoA-I, and apoA-II concentrations were
used with equation (9) and least-squares curve-fitting routines to
generate best-fit values for the parameters, k1 and k2, and
subsequently for the k2/k1 ratio (observed). In order to derive
Table 1. Clinical and laboratory characterization (mean6SD) and comparisons between base subjects and peak subjects in the
female low HDL-C/high CRP high-risk subgroup (HR1).
Parameter Total Population (N=879) Base (N=705) Peak (N=174) p-value
Clinical
CVD Outcomes %(N) 3.53(31) 2.13(15) 9.20(16) ,0.0001
Age (Years) 50.1612.3 48.5612.1 56.4611.3 ,0.0001
BMI (kg/m
2) 28.265.0 28.065.0 29.064.6 0.005
Hypertension (%) 49.0 43.9 69.5 ,0.0001
Metabolic Syndrome (%) 46.3 41.3 66.1 ,0.0001
Alcohol Use (%) 12.5 13.2 9.3 0.16
Smoking Status (%) 0.57
Never 31.9 31.6 33.3
Former 28.4 27.9 30.5
Current 39.7 40.5 36.2
Biomarkers
HDL-C (mmol/L) 1.0760.16 1.0760.16 1.0860.14 0.72
CRP (mg/L) 3.1662.24 3.1362.23 3.2962.29 0.36
apoE (g/L) 0.042260.0180 0.038060.0160 0.056960.0170 ,0.0001
apoA-I (g/L) 1.2860.20 1.2660.20 1.3760.18 ,0.0001
apoA-II (g/L) 0.32960.057 0.33260.059 0.31660.044 0.0001
apoA-II/apoA-I (Wt ratio) 0.25860.034 0.26560.034 0.23160.018 ,0.0001
HDL-C/apoA-I (mmol/g) 0.85360.228 0.86760.237 0.80060.177 ,0.0001
Cholesterol (mmol/L) 5.8761.18 5.7661.16 6.3161.19 ,0.0001
LDL-C (mmol/L) 4.0061.04 3.9361.00 4.2761.16 0.0016
Triglycerides (mmol/L) 1.7461.03 1.6661.01 2.0761.05 ,0.0001
apoB (g/L) 1.1560.33 1.1360.32 1.2260.33 0.0005
doi:10.1371/journal.pone.0039110.t001
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search was undertaken evaluating the k2/k1 ratio (predicted)
resulting from judiciously chosen combinations of the three
variables. Following recent work reporting that human LpA-I
contains from three to seven apoA-I molecules per particle [41], N
in the grid search was allowed to vary from 2 to 8 in 0.1
increments. For n and m, values were allowed to range from 1 to 8
in 0.1 increments. This procedure resulted in the sampling of
307,501 combinations. Estimates of N, n, and m were generated as
mean values of the three variables for those combinations of
variables that resulted in estimates of the k2/k1 ratio that were
within 1% of the observed value (the percentage of combinations
meeting the criterion ranged from 0.24% to 0.47% of the 307,501
sampled combinations).
4. LpA-I and LpA-I:A-II concentrations. Resulting values
of N, n, and m together with observed values of apoA-I and apoA-
II levels were used with equations (4) and (3) to estimate values for
LpA-I and LpA-I:A-II concentrations.
Statistical Analyses
Statistica 10.0 (StatSoft, Inc., Tulsa, OK) was used for statistical,
numerical, and graphical analyses. For continuous variables,
differences between groups were assessed using Mann-Whitney U
test; for categorical variables, differences between distributions
were assessed using chi square test. Kaplan-Meier and Cox
proportional hazards multivariable regression analyses were used
to follow outcomes over time. Multivariable models were adjusted
based on significance (p,0.10) in Cox univariate analysis for
clinical covariates (age, BMI, hypertension, metabolic syndrome,
ethanol use, and smoking), and blood biomarkers (HDL-C, CRP,
apoA-I, apoA-II, cholesterol, LDL-C, triglycerides, apoB, and
apoE). Continuous risk variables were treated as binary variables
(dichotomized as highest quartile versus combined lowest three
quartiles). Modeling of relationships was performed using least-
squares curve-fitting routines. Significance testing of all final
models was at the p,0.05 level.
Outcome event mapping [25,39], a graphical exploratory data
analysis tool, was used to identify high-risk subgroups as a function
of apoE levels and the apoA-II/apoA-I ratio. Briefly, a 3-
dimensional scatter plot was generated with CVD outcome on
the z-axis (coded 0 for no outcome and +1 for outcome) as a
function of two rank-transformed (to more evenly distribute
patients over the bivariate risk domain) risk parameters (x-axis,
apoE levels; y-axis, apoA-II/apoA-I ratio). A smoothing algorithm
is then applied which results in a surface (outcome event map)
where height above the bivariate x-y plane approximates the
outcome rate. Regions of high risk are manifested as peaks while
regions of low risk are manifested as valleys. Subjects contained
within peaks in the mappings comprise high-risk subgroups.
Results
A flow Diagram to Clarify the Design of the Study is given
in Figure 1
ApoA-II/apoA-I ratio and apoE-associated risk in the total
study population of women and men.
Table 2. Clinical and laboratory characterization (mean6SD) and comparisons between base subjects and peak subjects in the
female high HDL-C/high CRP high-risk subgroup (HR2).
Parameter Total Population (N=508) Base (N=426) Peak (N=82) p-value
Clinical
CVD Outcomes %(N) 2.95(15) 1.64(7) 9.76(8) ,0.0001
Age (Years) 48.5612.9 47.0612.7 56.5610.9 ,0.0001
BMI (kg/m
2) 27.064.8 26.864.9 27.664.2 0.055
Hypertension (%) 45.3 42.0 62.2 0.0008
Metabolic Syndrome (%) 12.3 10.4 22.5 0.0026
Alcohol Use (%) 17.0 16.0 22.2 0.17
Smoking Status (%) 0.11
Never 31.9 32.4 29.3
Former 34.1 35.5 26.8
Current 34.1 32.2 43.9
Biomarkers
HDL-C (mmol/L) 1.5560.21 1.5660.21 1.5460.21 0.48
CRP (mg/L) 5.0562.01 5.0262.00 5.2262.09 0.46
apoE (g/L) 0.037760.0133 0.034360.0114 0.052960.0102 ,0.0001
apoA-I (g/L) 1.5960.25 1.5860.26 1.6160.21 0.26
apoA-II (g/L) 0.37560.072 0.37460.076 0.37860.052 0.47
apoA-II/apoA-I (Wt ratio) 0.23760.034 0.23860.037 0.23460.013 0.68
HDL-C/apoA-I (mmol/g) 0.99760.186 1.0060.197 0.96160.111 0.097
Cholesterol (mmol/L) 5.6761.17 5.5261.10 6.4361.19 ,0.0001
LDL-C (mmol/L) 3.5361.09 3.4161.04 4.1761.15 ,0.0001
Triglycerides (mmol/L) 1.2760.55 1.2260.49 1.5860.72 ,0.0001
apoB (g/L) 1.0160.27 0.9860.26 1.1560.28 ,0.0001
doi:10.1371/journal.pone.0039110.t002
ApoA-II Influence on apoE Coronary Risk in Women
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39110Preliminary to investigating potential connections of apoE-
associated risk in conjunction with apoA-I and apoA-II in HDL
particles in previously identified female and male high-risk
subgroups, we first studied the total study population in this
regard. An outcome event map was generated for subjects of the
total study population as a function of the apoA-II/apoA-I ratio
and apoE level (Figure 2). The mapping shows a modest risk peak
at higher levels of the apoA-II/apoA-I ratio and high levels of
apoE. Cox proportional hazards regression was performed for
peak versus base subjects with adjustments for clinical covariates
and biomarkers demonstrating univariate significance level,
p,0.1. Results of multivariable Cox regression demonstrated
non-significance (p=0.17) for peak versus base subjects in a model
adjusted for gender, age, BMI, hypertension, metabolic syndrome,
smoking, and levels of apoA-I, apoA-II, apoB, apoE, total
cholesterol, CRP, HDL-C, and triglycerides.
ApoA-II/apoA-I ratio and apoE-associated Risk in
Subgroups
Extending investigations to previously identified high-risk
subgroups in women and men of potential connections of apoE-
associated risk in conjunction with apoA-I and apoA-II in HDL
particles, outcome event maps in women (Figure 3) and men
(Figure 4) were generated showing estimated CVD risk as a
function of apoE levels and the apoA-II/apoA-I ratio for the
lower-risk background subgroups (BG), the high-risk low HDL-C/
high CRP subgroups (HR1), and the high-risk high HDL-C/high
CRP subgroups (HR2). The plots demonstrated a well-defined
single high-risk peak occurring only for HR1 women (Figure 3B, at
low levels of the apoA-II/apoA-I ratio and at high levels apoE
levels) and for HR2 women (Figure 3C, at an intermediate but
narrow range of values for the apoA-II/apoA-I ratio and at high
apoE levels). In view of the lack of focused risk associations of apoE
and the apoA-II/apoA-I ratio in all three of the male and the
background subgroup in women, further analyses in these
subgroups were not pursued.
For the female HR1 and HR2 subgroups, higher-risk subjects
were taken to be those subjects contained in the peaks of the
outcome event mappings. Peak boundaries were taken to be at a
base level of risk at a value of 5.3% corresponding to the onset of
peaks. Figures 3B and 3C show iso-contour lines of risk at this
level. On this basis, subjects contained within the high-risk peak in
subsequent analyses were designated as ‘‘peak’’ and remaining
subjects as ‘‘base’’ Table 1 (HR1) and Table 2 (HR2) present
clinical and biomarker characterization along with statistical
comparison between respective base and peak subjects. For the
female HR1 subgroup (Table 1), results demonstrated for peak in
comparison to base subjects older age; higher BMI; more
hypertension and metabolic syndrome; higher levels of apoE,
apoA-I, apoA-II, total cholesterol, LDL-C, triglycerides, and
apoB; and lower apoA-II/apoA-I and HDL-C/apoA-I ratios. For
the female HR2 subgroup (Table 2), results demonstrated for peak
in comparison to base subjects older age, more hypertension and
metabolic syndrome, and higher levels of apoE, total cholesterol,
LDL-C, triglycerides, and apoB. Levels of HDL-C, apoA-I, apoA-
Figure 5. Kaplan-Meier plots for base subjects (heavy solid
line) and peak subjects (light solid line) for: A. the low female
HDL-C/high CRP subgroup (HR1) (p,0.0001, log-rank); and B.
the female high HDL-C/high CRP subgroup (HR2) (p,0.0001,
log-rank).
doi:10.1371/journal.pone.0039110.g005
Table 3. Best-fit parameters resulting from modeling of HDL-
C levels as a function of apoA-I and apoA-II levels and
comparison of resultant predicted values of mean HDL-C
levels with observed values of mean HDL-C levels in the
female low HDL-C/high CRP subgroup (HR1) and the female
high HDL-C/high CRP subgroup (HR2).
Base Subjects Peak Subjects
HR1
Best-fit parameters
k1 0.0222 0.0177
k2 0.0045 0.0126
k2/k1 0.2002 0.7089
Predicted mean HDL-C (mmol/L) 1.06 1.07
Observed mean HDL-C (mmol/L) 1.07 1.08
Difference (%) 20.93 20.93
HR2
Best-fit parameters
k1 0.0257 0.0203
k2 0.0060 0.0187
k2/k1 0.2331 0.9207
Predicted mean HDL-C (mmol/L) 1.53 1.53
Observed mean HDL-C (mmol/L) 1.56 1.54
Difference (%) 21.92 20.65
doi:10.1371/journal.pone.0039110.t003
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base subjects. With regard to the apoA-II/apoA-I ratio, although
mean values were not different between peak and base, the SD of
the ratio for peak subjects was approximated one third the value
for base subjects suggestive of a narrow range in the ratio
characterizing apoE-associated risk.
To confirm the high-risk nature of peak versus base subjects,
survival analysis was performed. Preliminary analyses revealed
follow-up times among the BG, HR1, and HR2 subgroups to be
comparable (p=0.079, Krukal-Wallis) as well as between base and
peak subjects of HR1 and HR2 (p=0.31 and p=0.69, respec-
tively, Mann-Whiney-U). Results of subsequent Kaplan-Meier
analysis demonstrated for the female HR1 subgroup significant
difference between the curves (Figure 5A, p,0.0001, log-rank) and
likewise for the female HR2 subgroup (Figure 5B, p,0.0001, log-
rank). In addition, Cox proportional hazards regression was
performed for peak versus base subjects with adjustments for
respective Cox univariate significant clinical covariates and
biomarkers for HR1 (age, BMI, hypertension, metabolic syn-
drome, HDL-C, cholesterol, triglycerides, and apoE) and HR2
(age, BMI, hypertension, cholesterol, LDL-C, triglycerides, apoB
and apoE). Results continued to reveal significantly higher risk for
peak subjects for both the HR1 subgroup (hazard ratio 2.44, 95%
CI 1.07–5.55, p=0.034) and the HR2 subgroup (hazard ratio
5.35, 95% CI 1.07–26.65, p=0.041).
LpA-I and LpA-I:A-II Concentrations
HDL-C concentration was modelled in terms of apoA-I and
apoA-II levels as detailed in the Materials and Methods section
resulting in the generation of best-fit values for the model
parameters, k1 and k2. Analyses were performed separately for
base and peak subjects with results given for the female HR1 and
HR2 subgroups in Table 3. Predicted values of mean HDL-C
levels agreed closely with corresponding observed values.
Estimates of LpA-I and LpA-I:A-II concentrations were
developed as described in the Materials and Methods section.
That is; values of N, n, and m resulting from grid searches based
upon comparison of predicted values of the k2/k1 ratio as a
function of N, n, and m combinations with the observed value of
the k2/k1 ratio were incorporated along with observed apoA-I and
apoA-II concentrations into equations (4) and (3) to generate
estimates of LpA-I and LpA-I:A-II concentrations for base and
peak subjects in the HR1 and HR2 subgroups (Table 4). For the
HR1 subgroup, peak subjects versus base subjects had per LpA-I
particle higher numbers of apoA-I molecules and per LpA-I:A-II
particle lower numbers of apoA-I molecules and similar numbers
of apoA-II molecules. For the HR2 subgroup, peak subjects versus
base subjects had per LpA-I particle higher numbers of apoA-I
molecules (similar to the HR1 subgroup) and per LpA-I:A-II
particle lower numbers of apoA-I molecules (similar to the HR1
subgroup); however, for LpA-I:A-II particles there were fewer
apoA-II molecules per particle in contrast to results for the HR1
subgroup. For the HR1 subgroup, peak versus base subjects
demonstrated higher levels of LpA-I particles and lower levels of
LpA-I:A-II particles. For the HR2 subgroup results were reversed;
peak versus base subjects showed lower levels of LpA-I particles
and higher levels of LpA-I:A-II particles.
Assessment of LpA-I and LpA-I:A-II Levels as Predictors of
Risk in HR1 and HR2 Subgroups LpA-I and LpA-I:A-II levels
(dichotomized as highest quartile versus combined lowest three
quartiles) were first entered into univariate Cox models. For HR1,
neither LpA-I (p=0.47) nor LpA-I:A-II (p=0.25) levels were
univariate significant; for HR2, LpA-I levels were not univariate
significant (p=0.13); whereas, LpA-I:A-II levels were univariate
significant (hazard ratio 8.35, 95% CI 2.21–31.46, p=0.0017).
Following the finding of univariate significance only for LPA-I:A-
II levels in HR2, multivariable modeling was pursued only in this
case. Models were adjusted for univariable significant biomarkers
Table 4. Estimates of apoA-I molecules/LpA-I particle (N), apoA-I molecules/LpA-I:A-II particle (n), and apoA-II molecules/LpA-I:A-II
particle (m); and estimates of LpA-I and LpA-I:A-II particle concentrations in base and peak subjects in the female HR1 and HR2
subgroups.
Base Subjects Peak Subjects p-value
HR1
Estimated molecules/particle
ApoA-I molecules/LpA-I particle (N) 5.0761.73 6.1461.33 ,0.0001
ApoA-I molecules/LpA-I:A-II particle (n) 4.1861.76 2.8661.34 ,0.0001
ApoA-II molecules/LpA-I:A-II particle (m) 4.4462.14 4.6261.84 0.027
Estimated particle concentrations
LpA-I (mM) 5.0561.00 5.8860.84 ,0.0001
LpA-I:A-II (mM) 4.3160.77 3.9360.54 ,0.0001
HR2
Estimated molecules/particle
ApoA-I molecules/LpA-I particle (N) 5.1561.68 6.3061.35 ,0.0001
ApoA-I molecules/LpA-I:A-II particle (n) 3.9361.70 2.7061.34 ,0.0001
ApoA-II molecules/LpA-I:A-II particle (m) 5.2261.75 3.9161.68 ,0.0001
Estimated particle concentrations
LpA-I (mM) 7.4661.41 6.5360.85 ,0.0001
LpA-I:A-II (mM) 4.1460.86 5.3560.74 ,0.0001
doi:10.1371/journal.pone.0039110.t004
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well as Cox univariate results for biomarkers and clinical
covariates. Models adjusted for significant biomarker and clinical
covariates (age, BMI, hypertension, cholesterol, LDL-C, triglyc-
erides, apoB and apoE) as a function of LpA-I:A-II levels revealed
continued significance of LpA-I:A-II levels (hazard ratio 5.31, 95%
CI 1.12–25.17, p=0.036) as a predictor of risk in the HR2
subgroup.
Relationship of apoA-II and apoE in the Establishment of
Risk in HR2 Females
To investigate the relationship of apoA-II to apoE-associated
risk in HR2, Kaplan-Meier analysis was performed as a function
of the four combinations of dichotomized levels of LpA-I:A-II and
apoE (Figure 6). The curve for subjects with high levels of both
LpA-I:A-II and apoE is notable in demonstrating greater risk than
any of the other three combinations (log-rank, p,0.0001; high
LpA-I:A-II/high apoE subjects compared to combined remaining
three lower-risk groups).
Discussion
We previously reported identification of two subgroups of
healthy women at high-risk for incident CVD, one with low HDL-
C and high CRP levels and the other with high HDL-C and high
CRP levels [21–23]. We believe the high CRP in each case to be
indicative of an underlying potentiating relationship between
inflammation and HDL particles in the establishment of risk. A
major finding of the current work was that high levels of HDL
particles with both apoA-I and apoA-II (LpA-I:A-II) associated
with incident CVD risk in the high-risk group of women with high
levels of HDL-C and CRP as determined by multivariable models
adjusted for relevant clinical covariates and blood markers. In the
same high-risk group, apoA-II levels were found not to be
associated with risk which was suggestive that apoA-II associated
risk derived not from the absolute amount of apoA-II but rather
from the number of particles of apoA-II-carrying HDL. An
additional important finding of the current study was that LpA-
I:A-II associated risk was found to interact positively with the
increased risk previously demonstrated for high levels of apoE in
these women [23]. Regarding HDL particles with apoA-I but not
apoA-II (LpA-I), there was no association of risk with LpA-I in the
high HDL-C/high CRP women. Also, it should be noted that for
women with low levels of HDL-C and high levels of CRP, neither
LpA-I:A-II nor LpA-I associated with risk.
As stated above, we found risk in the female high HDL-C/high
CRP subgroup associated with high levels of LpA-I:A-II particles
but not with apoA-II levels. Regarding CVD risk and apoA-II in
general, the situation is not clear in that although it is generally
thought that there is an inverse relationship of risk with apoA-II
levels, other studies indicate that apoA-II may be pro-atherogenic
[33,34]. Our lack of demonstrating apoA-II risk may thus be a
reflection of sensitivity of potential apoA-II associated risk to
salient features of specific populations. Regarding LpA-I:A-II and
risk, there are few human studies directly assessing potential
associations. One of particular relevance to the current study was
an investigation of LpA-I and LpA-I:A-II regarding atherosclerotic
lesions in hyperalphalipoproteinemic subjects. Results indicated
less cardioprotective effects for higher LpA-I:A-II levels [42].
Additionally, a report from the Framingham Offspring Study in an
investigation involving participants with and without coronary
heart disease revealed slightly but significantly higher levels of
LpA-I:A-II in cases versus HDL-C-matched controls [43]. On the
other hand, earlier studies revealed for LpA-I:A-II levels in
individuals with coronary artery disease as compared to controls,
in one case lower levels [44] and in another case no difference
[45].
With regard to apoA-II and lipoprotein metabolism, there have
been substantial efforts directed at elucidation of possible links.
Reported actions of apoA-II involve: primarily inhibitory effects
on remodeling of HDL through modulation of activities of lipid
transfer proteins (CETP, PLTP), enzymes (LCAT, LPL, HL,
endothelial lipase), and receptors (SR-B1, cubilin, heat shock
protein); efflux of cholesterol and phospholipids; and triglyceride
metabolism [26,27,30–33]. Recent work potentially relevant to
findings of the current study involved an investigation in human
subjects of apoA-II metabolism in the setting of raised levels of
HDL-C brought about by torcetrapib inhibition of CETP [33].
Results indicated delayed catabolism of and alterations in
remodeling of apoA-II containing HDL particles presumably
stemming from the large size of resultant particles and apoA-II
mediated inhibition of phospholipases (endothelial lipase and HL).
In addition to the previously mentioned effects of apoA-II on HDL
remodeling, lipid efflux, and triglyceride metabolism; human
apoA-II may play a role in the anti-oxidant properties of HDL
although the issue remains unclear. One study reported the
efficient transport by apoA-II rich HDL of two enzymes,
paraoxonase 1 (PON1) and platelet activating factor acetylhy-
Table 5. Biomarker dichotomzation cut-points (Q4 versus
Q1+Q2+Q3) and univariate results of Cox proportional
hazards regression for LpA-I and LpA-I:A-II particle
concentrations as predictors of risk as well as corresponding
values for biomarker and clinical covariates in the female high
HDL-C/high CRP (HR2) high-risk subgroup.
Parameter
Dichotomization
Cut-Off Level
Univariate HR
(95% CI) p
LpA-I 8.25 (mM) 0.17 (0.02–1.71) 0.13
LpA-I:A-II* 5.10 (mM) 8.35 (2.21–31.46) 0.002
Biomarkers
HDL-C 1.68 (mM) 0.46 (0.10–2.05) 0.31
CRP 6.42 (mg/L) 1.54 (0.53–4.50) 0.43
apoE* 0.0447 (g/L) 8.30 (2.20–31.28) 0.002
apoA-I 1.76 (g/L) 0.78 (0.22–2.75) 0.70
apoA-II 0.41 (g/L) 0.77 (0.22–2.72) 0.68
Cholesterol* 6.40 (mM) 4.55 (1.62–12.78) 0.004
LDL-C* 4.21 (mM) 2.61 (0.95–7.20) 0.064
Triglycerides* 1.53 (mM) 4.89 (1.74–13.75) 0.003
apoB* 1.18 (g/L) 3.46 (1.25–9.53) 0.017
Clinical Covariates
Age (Years)* 1.08 (1.03–1.13) 0.001
BMI (kg/m
2)* 1.10 (1.01–1.20) 0.022
Hypertension* 4.85 (1.37–17.18) 0.014
Metabolic Syndrome 1.13 (0.26–5.01) 0.87
Alcohol Use 1.22 (0.34–4.32) 0.76
Smoking Status 1.32 (0.70–2.51) 0.39
*Univariate significance at the p,0.10 level.
Adjustments to multivariable Cox models were made for biomarkers and
clinical covariates demonstrating p,0.1 level of significance in Cox univariate
analyses.
doi:10.1371/journal.pone.0039110.t005
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oxidant functionality of HDL [46]. However, another study
reported for human apoA-II enriched HDL, impaired protection
against oxidative modification of apoB-containing lipoproteins and
displacement of PON1 by apoA-II. This was thought to explain
why PON1 is found mostly on LpA-I particles and why, at least in
part, apoA-II-rich HDL demonstrated lack of anti-atherogenic
properties [47]. It should also be noted that studies in mice
involving apoA-II-enriched HDL have demonstrated pro-inflam-
matory transformation of HDL [48,49]. In addition to these
findings, a recent study reports novel apoA-II associated pro-
inflammatory activity in the suppression of lipopolysaccharide
(LPS) inhibition by LPS binding proteins [50]. The finding in the
current study of LpA-I:A-II associated risk would thus be
consistent with pro-inflammatory and pro-atherogenic character-
istics of apoA-II as noted above.
Results of the current study indicated positive interaction of
LpA-I:A-II with apoE in terms of CVD risk in the female high
HDL-C/high CRP subgroup (HR2). In this regard it may be
notable that apoA-II and apoE are known to form a heterodimeric
complex that overall accounts for approximately 30% of plasma
apoE in normolipidemic subjects; and furthermore, it has been
reported that the complex on HDL demonstrates reduced binding
affinity for the LDL receptor [51,52]. Thus, it is tempting to
speculate that the conditions of high-risk in the HR2 subgroup
(high LpA-I:A-II and apoE levels) could result, in part, through
formation of the apoE/apoA-II complex subsequently resulting in
reduced uptake of HDL-C via the LDL receptor-mediated uptake
pathway for apoE-rich HDL [53]. This could increase HDL
residence time in the circulation which could foster dysfunctional
transformation of HDL in the inflammatory setting indicated by
the high CRP defining the subgroup.
Limitations in the current study involved a number of issues.
Because the central aim of the study was to examine potential risk
in the female high HDL-C/high CRP subgroup as related to
apoA-II levels, and as preliminary studies revealed no evidence of
such risk not only for apoA-II but additionally for apoA-I; we
sought instead to extend our studies to LpA-I and LpA-I:A-II
particles. This necessitated an approach involving several
assumptions for the estimation of these parameters. The first of
these was that LpA-I and LpA-I:A-II constitute the major
subclasses of HDL. This appears justified in that although HDL
particles containing apoA-II without apoA-I have been reported
[54], they appear to comprise a small fraction of HDL, and in
general, they are not detected in the circulation [55]. Another
concern is that apoA-II is known to be present in VLDL [31];
however, this occurs in the setting of low plasma HDL-C levels
which was clearly not the case in the present study of the high
HDL-C subgroup. The second assumption was that HDL particle
concentration was in direct proportion to measured HDL-C.
Although it is known that LpA-I and LpA-I:A-II particles are
heterogeneous within each subclass with regard to size and density
and consequently cholesterol content; on average, the assumption
of direct proportionality seems reasonable. This notion is
supported by results of previous studies demonstrating statistically
significant linear correlation of HDL particle concentration with
HDL-C levels [56–58]. The third assumption was that the search
for the number of apoA-I and apoA-II molecules per particle
based upon goodness of fit to observed values of the k2/k1 ratio
would provide valid estimates. In this regard, our estimates
compared well with experimentally determined values from other
studies. The value of N (number A-I molecules/LpA-I particle) in
the current study ranged from 5.1 to 6.3 as compared to 3.0 to 7.0
over the total size range of HDL particles as reported in a recent
study [41]. Additionally, the ratio of number of A-I molecules to
number of A-II molecules in LpA-I:A-II particles in the current
study ranged from 0.62 to 0.94 comparing well with reported
values for human HDL of 1.00 [59,60], 1.20 [61], 1.30 [62], 1.56
[63], and 1.89 [64]. In addition to these points, there were other
limitations to the study including no direct data provided relating
Figure 6. Kaplan-Meier curves in the female high-HDL-C/high CRP subgroup (HR2) as a function of combinations of dichotomized
LpA-I:A-II and apoE levels as follows: light solid line - low LpA-I:A-II and low apoE, short dashes - low LpA-I:A-II and high apoE, long
dashes - high LpA-I:A-II and low apoE, and heavy solid line - high LpA-I:A-II and high apoE.
doi:10.1371/journal.pone.0039110.g006
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I:A-II as related to dysfunctional transformation of HDL in the
establishment of risk. These issues should be addressed in future
studies by assessment of multiple facets of HDL functionality as
well as physico-chemical characterization of HDL to elucidate the
nature of potential dysfunctional transformation in such popula-
tions.
In summary, we have studied a potential role for apoA-II in the
risk of incident CVD risk in a previously identified subgroup of
healthy women defined by high levels of HDL-C and CRP [21,22]
and for whom apoE was previously shown to be a risk factor [23].
Results of the current study demonstrated that high levels of apoA-
II containing HDL particles (LpA-I:A-II) also associated with
incident CVD risk using multivariable modeling adjusted for
relevant clinical and biochemical covariates. In addition, LpA-I:A-
II and apoE were found to interact positively in the establishment
of risk. Regarding other related factors, it should be noted that
neither HDL-C, nor HDL particles without apoA-II (LpA-I), nor
apoA-I, nor apoA-II levels associated with risk in the subgroup.
LpA-I:A-II associated risk in the absence of apoA-II associated risk
was suggestive that the number of LpA-I:A-II particles and not the
quantity of apoA-II was important in the establishment of such
risk. We conclude that apoA-II and apoE, major apolipoprotein
constituents of HDL, are important in the ongoing characteriza-
tion of the nature of HDL particles with regard to pathophysi-
ologic mechanisms responsible for high CVD risk in populations
with concurrently high levels of HDL-C and CRP.
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